Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
BioMarin Pharmaceutical Inc is a biotechnology business based in the US. BioMarin Pharmaceutical shares (BMRN) are listed on the NASDAQ and all prices are listed in US Dollars. BioMarin Pharmaceutical employs 3,001 staff and has a trailing 12-month revenue of around USD$1.8 billion.
Since the stock market crash in March caused by coronavirus, BioMarin Pharmaceutical's share price has had significant negative movement.
Its last market close was USD$77.11, which is 18.97% down on its pre-crash value of USD$95.16 and 12.98% up on the lowest point reached during the March crash when the shares fell as low as USD$68.25.
If you had bought USD$1,000 worth of BioMarin Pharmaceutical shares at the start of February 2020, those shares would have been worth USD$849.30 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$917.61.
|Latest market close||USD$77.11|
|52-week range||USD$67.1 - USD$131.945|
|50-day moving average||USD$76.9135|
|200-day moving average||USD$98.464|
|Wall St. target price||USD$110.48|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.676|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-23)||0.09%|
|1 month (2020-10-30)||3.60%|
|3 months (2020-08-28)||0.96%|
|6 months (2020-05-29)||-27.63%|
|1 year (2019-11-29)||-4.46%|
|2 years (2018-11-30)||-19.70%|
|3 years (2017-11-30)||-10.13%|
|5 years (2015-11-30)||-19.15%|
Valuing BioMarin Pharmaceutical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioMarin Pharmaceutical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
BioMarin Pharmaceutical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 117x. In other words, BioMarin Pharmaceutical shares trade at around 117x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
BioMarin Pharmaceutical's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.8439. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioMarin Pharmaceutical's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
BioMarin Pharmaceutical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$97.9 million.
The EBITDA is a measure of a BioMarin Pharmaceutical's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$1.8 billion|
|Gross profit TTM||USD$629.6 million|
|Return on assets TTM||-0.13%|
|Return on equity TTM||3.95%|
|Market capitalisation||USD$14 billion|
TTM: trailing 12 months
There are currently 11.7 million BioMarin Pharmaceutical shares held short by investors – that's known as BioMarin Pharmaceutical's "short interest". This figure is 14.1% up from 10.2 million last month.
There are a few different ways that this level of interest in shorting BioMarin Pharmaceutical shares can be evaluated.
BioMarin Pharmaceutical's "short interest ratio" (SIR) is the quantity of BioMarin Pharmaceutical shares currently shorted divided by the average quantity of BioMarin Pharmaceutical shares traded daily (recently around 2.3 million). BioMarin Pharmaceutical's SIR currently stands at 4.99. In other words for every 100,000 BioMarin Pharmaceutical shares traded daily on the market, roughly 4990 shares are currently held short.
However BioMarin Pharmaceutical's short interest can also be evaluated against the total number of BioMarin Pharmaceutical shares, or, against the total number of tradable BioMarin Pharmaceutical shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioMarin Pharmaceutical's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 BioMarin Pharmaceutical shares in existence, roughly 60 shares are currently held short) or 0.0737% of the tradable shares (for every 100,000 tradable BioMarin Pharmaceutical shares, roughly 74 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BioMarin Pharmaceutical.
Find out more about how you can short BioMarin Pharmaceutical stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like BioMarin Pharmaceutical.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 25.92
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and BioMarin Pharmaceutical's overall score of 25.92 (as at 10/01/2020) is nothing to write home about – landing it in it in the 42nd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like BioMarin Pharmaceutical is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 0.12/100
BioMarin Pharmaceutical's environmental score of 0.12 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that BioMarin Pharmaceutical is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 15.87/100
BioMarin Pharmaceutical's social score of 15.87 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that BioMarin Pharmaceutical is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 7.42/100
BioMarin Pharmaceutical's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that BioMarin Pharmaceutical is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. BioMarin Pharmaceutical scored a 1 out of 5 for controversy – the highest score possible, reflecting that BioMarin Pharmaceutical has managed to keep its nose clean.
|Total ESG score||25.92|
|Total ESG percentile||42.26|
|Environmental score percentile||1|
|Social score percentile||1|
|Governance score percentile||1|
|Level of controversy||1|
We're not expecting BioMarin Pharmaceutical to pay a dividend over the next 12 months.
Over the last 12 months, BioMarin Pharmaceutical's shares have ranged in value from as little as $67.1 up to $131.945. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioMarin Pharmaceutical's is 0.7286. This would suggest that BioMarin Pharmaceutical's shares are less volatile than average (for this exchange).
BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide, a peptide therapeutic that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; and BMN 307, an AAV5 mediated gene therapy to normalize blood phenylalanine concentration levels in patients with phenylketonuria. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd.; and a preclinical collaboration and license agreement with DiNAQOR AG for the development of gene therapies to treat rare genetic cardiomyopathies. The company was founded in 1996 and is headquartered in San Rafael, California.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.